Cell Biosciences Acquires Brightwell Technologies

SANTA CLARA, California, May 12, 2011 - Cell Biosciences, Inc. today announced that it has acquired Brightwell
Technologies, Inc. of Ottawa, Ontario for approximately U.S. $9 million in
cash.

Brightwell Technologies is the market leader in Micro-Flow Imaging (MFI),
an analytical technique used to detect particles and aggregates in
protein-based therapeutics. Because of high interest in protein aggregation
expressed by the FDA and other regulatory agencies, Brightwell's MFI products
have experienced widespread adoption by the world's largest pharmaceutical
and biotechnology companies. Brightwell was founded in 2001 and employs
approximately 30 people at its headquarters in Ottawa, Ontario. Brightwell's
2011 revenues are expected to be approximately U.S. $5 million.

The acquisition of Brightwell Technologies significantly strengthens Cell
Biosciences' position in the high-growth protein therapeutics market. Cell
Biosciences entered that market in October 2010, with the acquisition of
Convergent Bioscience. Convergent's products for protein characterization are
used by virtually every major producer of protein therapeutics. Because
Brightwell's MFI products are targeted at the same customer set, this
transaction is expected to fuel additional market penetration for both
product lines.

Commenting on the transaction, Tim Harkness, President and Chief
Executive Officer of Cell Biosciences, said, "Brightwell's MFI platform holds
the leading position in an important emerging market, and represents a great
strategic fit with existing Cell Biosciences products. This is our fourth
acquisition in 18 months and it represents another important step in our plan
to build a highly focused and differentiated protein analysis pure-play."

Peter Moore, President of Brightwell Technologies, added, "We are
extremely pleased to be joining Cell Biosciences. This transaction creates
exciting opportunities for our people, and the cultural fit between the two
organizations is ideal. Cell Biosciences' worldwide commercial infrastructure
will immediately take Brightwell's business to the next level."

In connection with the transaction, Cell Biosciences raised U.S. $13
million in a second tranche of its Series F Preferred Stock financing led by
Essex Woodlands Health Ventures. Existing investors, including Novo A/S,
Domain Associates, Latterell Venture Partners, Royal Bank of Canada, The
Vertical Group and Lansing Brown Investments, LLC, also participated in the
financing.

ABOUT CELL BIOSCIENCES

Cell Biosciences is a private life sciences company focused on defining
the future of protein analysis. The Company develops instrumentation systems,
software and assay products that help researchers better understand proteins
for fundamental research, biotherapeutics production, biomarker discovery and
personalized medicine. With an installed base of over 10,000 systems, its
customers include leading research institutions, pharmaceutical and
biotechnology companies worldwide. Cell Biosciences is headquartered in Santa
Clara, California. For more information, visit
www.cellbiosciences.com.

Tim Harkness, CEO of Cell Biosciences, Inc., +1-408-510-5501, tharkness at cellbiosciences.com